Holen Sie sich die Stockscreener-App
3.49
1.75%
0.06
Handel nachbörslich:
3.48
-0.01
-0.29%
Schlusskurs vom Vortag:
$3.43
Offen:
$3.43
24-Stunden-Volumen:
479.89K
Relative Volume:
0.39
Marktkapitalisierung:
$151.10M
Einnahmen:
$1.23M
Nettoeinkommen (Verlust:
$-28.62M
KGV:
-2.2232
EPS:
-1.5698
Netto-Cashflow:
$-14.11M
1W Leistung:
-1.69%
1M Leistung:
+14.43%
6M Leistung:
+86.63%
1J Leistung:
+32.70%
1-Tages-Spanne:
$3.39
$3.50
1-Wochen-Bereich:
$3.38
$3.545
52-Wochen-Spanne:
$1.62
$5.055
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Firmenname
Nrx Pharmaceuticals Inc
Sektor
Branche
Telefon
484-254-6134
Adresse
1201 ORANGE STREET, WILMINGTON
Compare NRXP vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
3.49 | 151.97M | 1.23M | -28.62M | -14.11M | -1.5698 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-04-02 | Eingeleitet | BTIG Research | Buy |
Nrx Pharmaceuticals Inc Aktie (NRXP) Neueste Nachrichten
NRX (NRXP) Momentum: Ends Higher by 5.41% at $3.51 for the Current Session; the Current Price Sits Inside the Supplied Technical RangeIV Contraction - Vinanet
NRx cites arbitration in Kadima acquisition dispute - scanx.trade
FDA First Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies Noted for Suicidal Bipolar Depression Treatment from NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - FinancialContent
NRx Pharmaceuticals, Inc. (NRXP) Stock Price, News, Quote & History - Yahoo Finance
Nrx Pharmaceuticals Earnings Call Signals Cautious Momentum - TipRanks
NRx Pharmaceuticals Targets 2026 KETAFREE Approval, Advances DARPA-Backed Depression Trial - citybiz
NRx Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
BTIG Maintains NRX Pharmaceuticals(NRXP.US) With Buy Rating, Cuts Target Price to $10 - moomoo.com
BTIG Research Reaffirms "Buy" Rating for NRx Pharmaceuticals (NASDAQ:NRXP) - MarketBeat
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update - marketscreener.com
NRX Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
NRX Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
NRx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET - Investing News Network
NRX Pharmaceuticals Q2 Results: EPS Misses Estimate, Sales Fall 94% - scanx.trade
NRX Pharmaceuticals reports $18.0M net loss for first half 2026, $26.7M cash on hand - TradingView
Press Release: NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to Be Held on Monday, August 17th at 4:30pm ET - Moomoo
NRX Pharmaceuticals earnings missed by $0.33, revenue fell short of estimates - Investing.com Nigeria
NRx Pharmaceuticals, Inc. (NRXP) reports Q2 loss, misses revenue estimates - FXStreet
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
NRx Pharmaceuticals (NASDAQ:NRXP) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
NRx Pharmaceuticals (NASDAQ:NRXP) Issues Earnings Results, Misses Estimates By $0.35 EPS - MarketBeat
NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
NRX Pharmaceuticals | 10-Q: Q2 2026 Earnings Report - Moomoo
NRx Pharmaceuticals (NRXP) grows clinic revenue, flags going concern risk - Stock Titan
NRXP Stock Price, Quote & Chart - ChartMill
NRX Pharmaceuticals Inc expected to post earnings of 6 cents a shareEarnings Preview - TradingView
NRXP Q2'26 Earnings: EPS estimate is (0.11) USD - TradingView
NRX Pharmaceuticals Inc (NRXP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
GOOGL Stock Price TodayAlphabet Inc Class A News, Charts, Retail Sentiment - Stocktwits
H.C. Wainwright reiterates NRx Pharmaceuticals stock rating at buy By Investing.com - Investing.com UK
NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles - MarketBeat
Transcript : NRx Pharmaceuticals, Inc.Special Call - marketscreener.com
H.C. Wainwright reiterates NRx Pharmaceuticals stock rating at buy - Investing.com
NRx Pharmaceuticals (NRXP) Projected to Post Quarterly Earnings on Monday - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO) and Pfizer (PFE) - The Globe and Mail
NRx Advances FDA Review of Ketamine ANDA Packaging Issue - The Globe and Mail
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans - The Manila Times
NRX Pharmaceuticals Inc (NRXP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NRx Pharmaceuticals completes FDA first-cycle ANDA review By Investing.com - Investing.com South Africa
NRx Pharmaceuticals to discuss FDA review and c... - Pluang
NRx Pharmaceuticals to Host Conference Call on FDA First-Cycle Review of Preservative-Free Ketamine ANDA - Quiver Quantitative
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference - GlobeNewswire
NRx Pharmaceuticals Shares Rise After FDA Finishes Ketamine Review - Moomoo
BTIG Research Cuts NRx Pharmaceuticals (NASDAQ:NRXP) Price Target to $10.00 - MarketBeat
FDA Clears Major Regulatory Hurdle as Preservative-Free Ketamine Program Moves Within Reach of Commercialization: NRx Pharmaceuticals: (NAS DAQ: NRXP) - FinancialContent
NRx Pharma rises on FDA review of ketamine ANDA (NRXP:NASDAQ) - Seeking Alpha
NRX Pharmaceuticals Inc. R (B1Q.MU) Q1 FY2026 earnings call transcript - Yahoo Finance
NRx Pharmaceuticals completes FDA first-cycle ANDA review - Investing.com
FDA Completes First-Cycle Review of Preservative-Free - GlobeNewswire
Certain Common Stock of NRx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-AUG-2026. - marketscreener.com
12 Health Care Stocks Moving In Friday's After-Market Session - Sahm
Finanzdaten der Nrx Pharmaceuticals Inc-Aktie (NRXP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):